The COMPLeMENT trial is a prospective, pragmatic RCT of printed, evidence-based educational material that incorporates a no-intervention control.
Additional data, particularly from observational studies, would provide needed real-world evidence to complement trial-based data on the patient-reported benefits associated with ivacaftor treatment.
Although the limitations can be daunting, including autocorrelation, time varying external effects, non-linearity, and unmeasured confounding, quasi-experimental designs are much cheaper and have the capacity, when carefully conducted, to complement trial evidence or even to map uncharted territory.
Our results complement trial results by documenting that among a general population of women diagnosed with breast cancer, tamoxifen treatment does not appear to increase or decrease MI risk, and suggest that prevention of MI should not be considered an advantage of tamoxifen use.
Moreover, pharmacological interventions in "naturalistic" patients populations, selected by clinicians as per clinical judgment within the scope of the target disease will allow to generate data to complement clinical trials.
Representative, population-based seroprevalence studies complement clinical trials and provide this key evidence.
This allows us to complement human trials with invasive experiments in animal models.
Therefore it is very important to complement ROC trials with other performance metrics that combine different classes of the confusion matrix and are consequently sensitive to class skew.
Our results complement initial trials demonstrating that not only the conversion of CTC-counts to a favorable level of <5 CTCs, but also a percent decrease shows a prognostic value for survival in mCRPC patients as it was demonstrated initially for OS by using a proportional fall of ≥30%% of continuously assessed CTC-counts [ 11].
Population-based epidemiological studies are uniquely suited to complement clinical trials of new vaccines, can aid in the investigation of the duration of protection, and are especially informative when newly developed vaccines are evaluated and licensed on the basis of immunogenicity alone, as in the case of PsA-TT.
